Charles River Laboratories International, Inc.
CRL · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $7 | $8 | $9 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $3 | $3 | $3 | $3 |
| Enterprise Value | – | $10 | $11 | $12 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -2.6% | 4.9% | -1.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 33.7% | 34.6% | 32.3% | 28.4% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 19.7% | 21.4% | 18.7% | -8.6% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 5.4% | 5.1% | 2.6% | -21.5% |
| EPS Diluted | 1.1 | 1.06 | 0.5 | -4.22 |
| % Growth | 3.8% | 112% | 111.8% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |